The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer

ConclusionIntermittent first- and second-line chemotherapy in patients with HER2-negative advanced  breast cancer showed a trend for worse impact on QoL compared to continuous chemotherapy, with neither significant nor meaningful differences in course. We recommend prescribing chemotherapy continuously until progressive disease or unacceptable toxicity.Trial registration EudraCT 2010-021519-18; BOOG 2010-02
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research